Join to View Full Profile
300 Pasteur DrPalo Alto, CA 94305
Phone+1 650-723-4000
Dr. Kurian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford University School of MedicineM.Sc., 2004 - 2006
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2002 - 2003
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Stanford UniversityB.A., 1991 - 1995
Certifications & Licensure
CA State Medical License 2002 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples Start of enrollment: 2001 Aug 01
Publications & Presentations
PubMed
- Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study.Jagadeswara Rao Earla, Kalé Kponee-Shovein, Allison W Kurian, Malena Mahendran, Yan Song
Journal of Medical Economics. 2025-12-01 - Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer.Manami Bhattacharya, Benmei Liu, Allison W Kurian, Jennifer Stevens, Lindsey Enewold
Breast Cancer Research and Treatment. 2025-04-01 - Extended endocrine therapy use and decision making after breast cancer diagnosis.Allison W Kurian, Allison K C Furgal, Archana Radhakrishnan, Christine M Veenstra, Paul Abrahamse
Journal of the National Cancer Institute. 2025-03-31
Journal Articles
- Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic VariantsMary B Daly, Sarah Colonna, Saundra S Buys, Allison W Kurian, JAMA Oncology
- Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—ReplyAllison W Kurian, Steven J Katz, JAMA
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingWilliam J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health
- Join now to see all
Lectures
- Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018
Press Mentions
Less Than 50% of Women with Breast Cancer Resume Endocrine Therapy After PregnancyApril 2nd, 2025- HMN 2025: How Research Gives Reassurance for Sufferers with Some Cancer-Linked GenesMarch 29th, 2025
- New Study Offers Reassurance for Patients with Some Cancer-Linked GenesMarch 27th, 2025
- Join now to see all
Grant Support
- Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink StudySTANFORD UNIVERSITY2024–2029
- A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK TrialUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
